Kobo Biotech Ltd (BSE: 531541) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹10 Cr, it ranks #5,040 by market cap among the 6,137 Indian listed companies on FinBizNet, and #83 of 86 in Medicinal Chemicals and Botanical Products. At ₹4.10 (as of 25 Oct 2026), the share price is 59.0% below its 52-week high of ₹9.99 and 106.0% above its 52-week low of ₹1.99. The share price is up 67.3% over one year and down 53.9% over three months.
| Current Price | ₹4.10 |
|---|---|
| Market Cap | ₹10 Cr |
| BSE Code | 531541 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -1.9 |
| Return on Equity | 3.78% |
| Return on Assets | -4.49% |
| 52-Week Range | ₹1.99 – ₹9.99 |
| 1-Year Price Change | +67.3% |
| 3-Month Price Change | -53.9% |
| Beta (1Y) | -0.08 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.kobobiotech.com |
Kobo Biotech Limited manufactures active pharmaceutical ingredients based on fermentation technology in India. The company was formerly known as Avon Lifesciences Limited and changed its name to Kobo Biotech Limited in October 2020. Kobo Biotech Limited was incorporated in 1993 and is based in Mumbai, India.
1. Manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs-This segment engages in the manufacture, sale, and export of pharmaceutical products. 2. Biotech-This segment manufactures diketene. 3. Diketene-This segment manufactures mollasses and benzaldehyde. 4. Bio-Tech-This segment manufactures mollasses and benzaldehyde.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Kobo Biotech Ltd | ₹10 Cr | -1.9 | 3.78% | — | +67.3% |
Listed by market capitalisation. Ratios are shown for context only.
Kobo Biotech Ltd is trading at ₹4.10, with a market capitalisation of ₹10 Cr.
Kobo Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kobo Biotech Ltd has a P/E of -1.9 and a return on equity of 3.78%.
Kobo Biotech Ltd is listed on the BSE under the scrip code 531541.
Kobo Biotech Ltd's share price is up 67.3% over one year and down 53.9% over three months. Its 52-week range is ₹1.99 to ₹9.99.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.